Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111657 · ClinicalTrials.gov registry record · Phase 2
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
A Phase 2 study, sponsored by John Sundy.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00111657: Completed Phase 2 study, sponsored by John Sundy.
NCT00111657 is a Phase 2 study that has completed, run by John Sundy. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111657, a Phase 2 study, has completed, sponsored by John Sundy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in patients with chronic gout, who cannot tolerate, or have not responded adequately, to conventional therapy for gout. Funding Source - FDA OOPD
Interventions
- BIOLOGICAL Pegloticase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111657
The ClinicalTrials.gov registry entry for NCT00111657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Sundy, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegloticase is the first listed.
NCT00111657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111657 about?
NCT00111657 is a clinical study titled "Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout". The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in patients with chronic gout, who cannot tolerate, or have not responded adequately, to conventional therapy for gout....
What is the current status of trial NCT00111657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00111657?
The interventions under investigation include: Pegloticase (BIOLOGICAL).
Who is sponsoring clinical trial NCT00111657?
This trial is sponsored by John Sundy, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.